Truvestments Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Truvestments Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$59.1K	Sell	119 -41	-26%	-$18.2K	0.01%	499
2026 Q1	$71.4K	Sell	160 -4	-2%	-$1.86K	0.01%	447
2025 Q4	$74.4K	Sell	164 -5	-3%	-$2.15K	0.01%	389
2025 Q3	$66.2K	Buy	169 +33	+24%	+$13.8K	0.01%	402
2025 Q2	$60.5K	Buy	136 +40	+42%	+$18.4K	0.01%	368
2025 Q1	$46.5K	Sell	96 -3	-3%	-$1.4K	0.01%	411
2024 Q4	$39.9K	Buy	99 +23	+30%	+$10.7K	0.01%	404
2024 Q3	$35.3K	Buy	+76	New	+$36.5K	0.01%	411
2023 Q1	–	Sell	-2	Closed	-$578	–	938
2022 Q4	$578	Buy	+2	New	+$610	﹤0.01%	859
2021 Q1	–	Sell	-55	Closed	-$12K	–	685
2020 Q4	$12K	Buy	+55	New	+$12.6K	0.01%	419
2020 Q3	–	Sell	-5	Closed	-$1K	–	548
2020 Q2	$1K	Buy	+5	New	+$1.36K	﹤0.01%	554
2019 Q4	–	Sell	-31	Closed	-$5K	–	583
2019 Q3	$5K	Hold	31	–	–	﹤0.01%	583
2019 Q2	$6K	Hold	31	–	–	﹤0.01%	604
2019 Q1	$6K	Buy	+31	New	+$5.73K	﹤0.01%	586
2018 Q3	$6K	Buy	+31	New	+$5.52K	﹤0.01%	722

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Truvestments Capital's VRTX Position: Q2 2026 in Review

Truvestments Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 26% in Q2 2026, selling an estimated $18.2K and leaving 119 shares worth $59.1K. The position accounts for 0.01% of the portfolio, ranked #499.

Truvestments Capital first reported a position in VRTX in Q3 2018 and has held it in 15 quarters since. The position peaked at $74.4K in Q4 2025. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Truvestments Capital held 119 shares of Vertex Pharmaceuticals worth $59.1K as of Q2 2026.
Truvestments Capital sold 41 Vertex Pharmaceuticals shares in Q2 2026, an estimated $18.2K.
Vertex Pharmaceuticals made up 0.01% of Truvestments Capital's portfolio in Q2 2026, its #499 holding.
Truvestments Capital first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 15 quarters since.
Truvestments Capital's Vertex Pharmaceuticals position peaked at $74.4K in Q4 2025.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.